Pharmabiz10h
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...
Business Wire14d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...
Pharmabiz2d
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
Medscape8mon
Trastuzumab Deruxtecan: Effects in Multiple Cancer Types
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...
pharmaphorum2y
FDA gives Daiichi Sankyo's HER3 drug a breakthrough tag
Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The designation ...
Nature22d
Billion-dollar bets on antibody–drug conjugates
For example, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan ... the hydrophobicity of the topoisomerase 1 inhibitor exatecan, enabling a high drug–antibody ratio (DAR ...
La Razón Digital7d
Ya está disponible trastuzumab deruxtecán contra el cáncer de mama metastásico HER2-low en todas las autonomías
La investigación continúa. De hecho, como ha demostrado el estudio "Destiny Breast 06", presentado este año, trastuzumab-deruxtecan mejora resultados en cáncer de mama metastásico en ...
The Globe and Mail8d
HR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with ...
Finanznachrichten1d
AstraZeneca PLC: Dato-DXd new BLA submitted, NSQ BLA withdrawn
Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor ...
London South East23d
Avacta Group Share Chat (AVCT)
The market leading antibody-drug conjugate, Enhertu (co-owned by Daiichi Sankyo and AstraZeneca), uses a derivative of exatecan (deruxtecan) as its warhead. Note that the consensus forecast is for ...
Morningstar14d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
Datopotamab deruxtecan is a specifically engineered ... attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.
ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product
ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...